Related Experiment Video
Updated: Feb 12, 2026

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
Published on: July 3, 2020
Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models
Simon Buatois1,2,3, Sebastian Ueckert4, Nicolas Frey5
1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. simon.buatois@inserm.fr.
Model averaging (MA) improves drug development predictions over model selection (MS) by accounting for model uncertainty. This approach enhances dose finding in clinical trials and accurately characterizes dose-response relationships.
Area of Science:
- Pharmacometrics and Drug Development
- Clinical Trial Simulation
- Statistical Modeling
Background:
- Pharmacometric approaches in drug development often use model selection (MS) to identify the best data-describing model structure.
- Using a single selected model for predictions neglects model structure uncertainty, potentially reducing predictive performance.
- Model averaging (MA) addresses this by incorporating uncertainty across multiple candidate models, weighted by information criteria.
Purpose of the Study:
- To compare the predictive performance of model selection (MS) versus model averaging (MA) in dose-finding clinical trials using clinical trial simulations (CTSs).
- To evaluate the performance of MA and MS using the Akaike Information Criterion (AIC) and four other information criteria.
- To assess the impact of these approaches on characterizing dose-response relationships and identifying minimum effective doses.
Main Methods:
- Clinical trial simulations (CTSs) were employed to compare MS and MA.
- A nonlinear mixed-effects model was used to simulate the visual acuity time course in wet age-related macular degeneration patients.
- Predictive performance was assessed using criteria relevant to Phase II clinical trial objectives.
Main Results:
- Model averaging (MA) demonstrated superior predictive performance compared to model selection (MS).
- MA improved the accuracy of dose-response relationship characterization and minimum effective dose identification.
- The Akaike Information Criterion (AIC) was associated with the best predictive performance, irrespective of the modeling approach (MA or MS).
Conclusions:
- Model averaging (MA) is a more robust approach than model selection (MS) for predictive modeling in dose-finding clinical trials.
- MA enhances the reliability of characterizing dose-response relationships and determining optimal drug dosages.
- AIC remains a valuable criterion for model evaluation, showing strong performance in predictive tasks within this simulation framework.
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
The Quantum-Mechanical Model of an Atom
Molecular Models
Drug Distribution as One-Compartment Model and Elimination by Nonlinear Pharmacokinetics: Overview
For instance, consider the metabolism of sodium salicylate. This compound is metabolized into two distinct substances: a glucuronide and a glycine conjugate. The rate of conjugation depends...
Stereotype Content Model

